References
- Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology 1997;48\(Suppl. 3):S4–9
- Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993;43 (Suppl. 3):S6–10
- Clarke CE, MacMillan L, Sondhi S, Wells NE. Economic and social impact of migraine. QJM 1996;89:77–84
- Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992;2:103–15
- van Roijen L, Essink-Bot ML, Koopmanschap MA, Michel BC, Rutten FF. Societal perspective on the burden of migraine in The Netherlands. Pharmacoeconomics 1995;7:170–9
- Warshaw LJ, Burton WN. Cutting the costs of migraine: role of the employee health unit. J Occup Environ Med 1998;40:943–53
- Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988;8\(Suppl. 7):1–96
- Stang P, Cady R, Batenhorst A, Hoffman L. Workplace productivity. A review of the impact of migraine and its treatment. Pharmacoeconomics 2001;19:231–44
- McCullagh P, Nelder JA. Generalized Linear Models. 2nd edn. New York, NY: Chapman and Hall, 1989
- Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System. 2nd edn. Cary, NC: SAS Institute, 2000
- Bigal ME, Moraes FA, Fernandes LC, Bordini CA, Speciali JG. Indirect costs of migraine in a public Brazilian hospital. Headache 2001;41:503–8
- Pop PH, Gierveld CM, Karis HA, Tiedink HG. Epidemiological aspects of headache in a workplace setting and the impact on the economic loss. Eur J Neurol 2002;9:171–4
- Michel P, Dartigues JF, Lindoulsi A, Henry P. Loss of productivity and quality of life in migraine sufferers among French workers: results from the GAZEL cohort. Headache 1997;37:71–8
- Schneider WJ, Furth PA, Blalock TH, Sherrill TA. A pilot study of a headache program in the workplace. The effect of education. J Occup Environ Med 1999;41:202–9
- Pascual J, Fite B, Lopez-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache 2002;42:93–8
- Leira R, Dualde E, del Barrio H, Machuca M, Lopez-Gil A. Almotriptan versus rizatriptan in patients with migraine in Spain. Headache 2003;43:734–41
- Streator SE, Shearer SW. Pharmacoeconomic impact of the injectable sumatriptan on migraine-associated healthcare costs. Am J Manag Care 1996;2:139–43
- Legg RF, Sclar DA, Nemec NL, Tarnai J, Mackowiak JI. Cost-effectiveness of sumatriptan in a managed care population. Am J Manag Care 1997;3:117–22
- Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patents with migraine treated with sumatriptan: a managed care perspective. Arch Intern Med 1999;159:857–63
- Burton WN, Morrison A, Wertheimer AI. Pharmaceuticals and worker productivity loss: a critical review of the literature. J Occup Environ Med 2003;45:610–21
- Lemstra M, Stewart B, Olszynski WP. Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. Headache 2002;42:845–54
- Davies GM, Santanello N, Gerth W, Lerner D, Block GA. Validation of a migraine work and productivity loss questionnaire for use in migraine studies. Cephalalgia 1999;19:497–502
- Dasbach EJ, Carides GW, Gerth WC, Santanello NC, Pigeon JG, Kramer. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia 2000;20:830–834
- Cady RC, Ryan R, Jhingran P, O’Quinn S, Pait DG. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med 1998;158:1013–8
- Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000;75:782–9
- Garcia-del-Pozo J, Carvajal A, Grajal C, Vera E, del Pino A. Antimigraine drug consumption in Spain (1990–2000). Acta Neurol Scand 2003;107: 158–60